American Journal of Cardiology
Volume 100, Issue 9 , Pages 1416-1418 , 1 November 2007

Effect of Low-Density Lipoprotein Apheresis on Inflammatory and Noninflammatory High-Density Lipoprotein Cholesterol

  • Isaac O. Opole, MD, PhD

      Affiliations

    • Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas
    • ,
  • John M. Belmont, PhD

      Affiliations

    • Department of Pediatrics, University of Kansas Medical Center, Kansas City, Kansas.
    • ,
  • Amit Kumar, MD

      Affiliations

    • Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas
    • ,
  • Patrick M. Moriarty, MD

      Affiliations

    • Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas
    • Division of Clinical Pharmacology, University of Kansas Medical Center, Kansas City, Kansas
    • Corresponding Author InformationCorresponding author: Tel: 913-588-6057; fax: 913-588-4074.

Received 21 February 2007 ,Revised 22 May 2007 ,Accepted 3 June 2007.

Reference 

  1. Sachais BS, Katz J, Ross J, Rader DJ. Long-term effects of LDL apheresis in patients with severe hypercholesterolemia. J Clin Apher. 2005;20:252–255
  2. Moriarty PM, Gibson CA. Effect of low-density lipoprotein apheresis on lipoprotein-associated phospholipase A2. Am J Cardiol. 2005;95:1246–1247
  3. Moriarty PM, Gibson CA, Shih J, Matias MS. C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis. Atherosclerosis. 2001;158:495–498
  4. Seidel D. The HELP system: an efficient and safe method of plasma therapy in the treatment of severe hypercholesterolemia. Ther Umsch. 1990;47:514–519
  5. Gordon BR, Saal SD. Low-density lipoprotein apheresis using the Liposorber dextran sulfate cellulose system for patients with hypercholesterolemia refractory to medical therapy. J Clin Apher. 1996;11:128–131
  6. Yamamoto T, Yamashita T. Low-density lipoprotein apheresis using the Liposorber system: features of the system and clinical benefits. Ther Apher. 1998;2:25–30
  7. Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, et al Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest. 1991;88:2039–2046
  8. Fogelman AM, Elahi F, Sykes K, Van Lenten BJ, Territo MC, Berliner JA. Modification of the Recalde method for the isolation of human monocytes. J Lipid Res. 1988;29:1243–1247
  9. Richter WO, Jacob BG, Ritter MM, Suhler K, Vierneisel K, Schwandt P. Three-year treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal apolipoprotein B antibodies. Metabolism. 1993;42:888–894
  10. Kroon AA, van’t Hof MA, Demacker PN, Stalenhoef AF. The rebound of lipoproteins after LDL-apheresis (Kinetics and estimation of mean lipoprotein levels). Atherosclerosis. 2000;152:519–526
  11. Schmaldienst S, Banyai S, Stulnig TM, Heinz G, Jansen M, Horl WH, et al. Prospective randomised cross-over comparison of three LDL-apheresis systems in statin pretreated patients with familial hypercholesterolaemia. Atherosclerosis. 2000;151:493–499
  12. Davidson WS, Sparks DL, Lund-Katz S, Phillips MC. The molecular basis for the difference in charge between pre-beta- and alpha-migrating high density lipoproteins. J Biol Chem. 1994;269:8959–8965
  13. Nowicka G, Bruning T, Bottcher A, Kahl G, Schmitz G. Macrophage interaction of HDL subclasses separated by free flow isotachophoresis. J Lipid Res. 1990;31:1947–1963
  14. Shao B, Oda MN, Oram JF, Heinecke JW. Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein. Curr Opin Cardiol. 2006;21:322–328

PII: S0002-9149(07)01460-9

doi: 10.1016/j.amjcard.2007.06.033

American Journal of Cardiology
Volume 100, Issue 9 , Pages 1416-1418 , 1 November 2007

Article Tools

* Image Usage & Resolution